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The authors present the use of prostaglandin E1 (PGE1) for the treatment of an acute paracentral 
acute middle maculopathy (PAMM). A 78-year-old white female was seen with a sudden loss of 
vision in her left eye (OS) to 20/200 noted upon awakening. The right eye (OD) saw 20/20. A 
complete eye exam was done and an ocular coherent tomography revealed retinal thickening and 
a whitening of the inner nuclear layer in the area of the macula OS. A diagnosis of PAMM in the 
OS was made. Treatment was immediately started with 70 μg of PGE1 administered over 1.5 hours 
in the form of a skin cream. A volume of 3.5 cc of skin cream was applied in divided doses to the 
inner surface of the forearm, rubbed into the skin and allowed to dry. The same 70 μg of PGE1 in 
3.5 cc of skin cream was repeated once the next morning. The patient began to see better the second 
day of treatment with a final visual acuity of 20/20. The OD was unchanged. After 14 months she 
was stable with no further treatment. PAMM is an ischemic process of the inner retina. PGE1, a 
potent vasodilator of the microcirculation, when given immediately seemed to be useful in restoring 
vision in this form of retinal ischemia. Treatment was immediately started with PGE1 in the form 
of a skin cream with visual improvement. The authors normally use PGE1 intravenously for acute 
ocular ischemia and would have preferred that here. Intravenous PGE1 was not available and was 
substituted with the skin cream of PGE1 that worked well for the patient.
1. Introduction
Paracentral acute middle maculopathy (PAMM) is the 
spectral domain-optical coherent tomography (SD-
OCT) finding of a hyperreflective band involving the 
inner nuclear layer (INL) resulting from ischemia at the 
level of the deep vascular complex which is made up of 
the intermediate and deep retinal capillary plexus of the 
retina (1). Perivenular retinal whitening can be seen in 
the macula. The final visual acuity can vary and there is 
no known therapy for the ischemic lesion in the retina. 
 Prostaglandin E1 (PGE1), a powerful vasodilator 
of the microcirculation, improves ocular blood flow in 
the presence of peripheral vascular disease and diabetes 
(2). In cases of acuity ocular ischemia, intravenous 
(i.v.) PGE1 given 1 μg/kg leads to visual improvement. 
In nonarteritic anterior ischemic optic neuropathy (3) 
and nonarteritic posterior ischemic optic neuropathy 
(4,5), i.v. PGE1 with steroids was shown to improve the 
visual acuity as well as the ocular and retrobulbar blood 
flow. An acute branch retinal arterial occlusion has also 
been successfully treated (6). In this case report PGE1 
was not immediately available for i.v. administration 
but only in the form of a skin cream. Since treatment 
could not be delayed, PGE1 was given in the form of a 
skin cream in the same dosage that would be used i.v. 
This appeared to be successful which will be explained 
in the paper. 
2. Case Report
A 78-year-old white female was seen in the morning 
of December 12, 2018 with a sudden loss of vision 
in her left eye (OS) noted upon awakening. She was 
under treatment for ocular hypertension and anemia. 
She was 20/20 in her right eye (OD) and 20/200 in 
the OS measured using the Early Treatment Diabetic 
Retinopathy Study letter scoring. There was a white 
inferior parafoveal semicircular lesion 1 disc diameter 
in width OS. SD-OCT revealed retinal thickening and 
a hyperreflective band in the INL extending into the 
inner retina (Figure 1 panel A). A diagnosis of PAMM 
in the OS was made. After explaining the urgency of 
the situation, written informed consent was obtained for 
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treatment and for the collection of clinical information 
for archival and research purposes. The patient weighed 
70 kg. The normal dosage of i.v. PGE1 to treat acute 
ocular ischemia is 1 μg/kg or 70 μg in this case. IV 
PGE1 was not available so treatment was immediately 
started with 70 μg of PGE1 administered over 1.5 hours 
in the form of a skin cream. A quantity of 3.5 cc of skin 
cream was applied in divided doses to the inner surface 
of the forearm, rubbed into the skin and allowed to 
dry. The same 70 μg of PGE1 in 3.5 cc of skin cream 
was repeated once the next morning. The patient noted 
visual improvement during the second day of treatment 
but was seen 9 days later on December 21, 2018. The 
acuity of the OD was stable and in the OS improved 
to 20/20. At that time the SD-OCT showed decreased 
retinal thickening with a reduction of the white lesion of 
the INL. (Figure 1 panel B). No further treatment with 
PGE1 was done. She was last seen on February 12, 2020 
with 20/20 OS. 
3. Discussion
The patient was seen with an acute ischemic episode of 
PAMM in the OS. Treatment was immediately started 
with PGE1 in the form of a skin cream with visual 
improvement. The authors normally use i.v. PGE1 for 
acute ocular ischemia (3-6) and would have preferred 
that here. With i.v. treatment in acute ocular ischemia, the 
authors are more certain to achieve clinically significant 
therapeutic levels. IV PGE1 was not available and was 
substituted with a topical skin cream of PGE1 which 
worked well for the patient. The authors however still 
recommend i.v. treatment in this form of acute ocular 
ischemia. 
 It is also important to note that treatment was 
started immediately and that this case of PAMM was 
treated only once over 2 days. Good visual acuity was 
maintained for 14 months without further treatments. 
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Figure 1. Spectral domain-ocular coherent tomography (SD-OCT) 
of the left eye of the patient. (panel A) before treatment revealed 
retinal thickening and a whitening of the inner nuclear layer (INL); 
(panel B) 9 days after treatment showed decreased retinal thickening 
with a reduction of the white lesion of the INL.
